A251120 Stock Overview
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
BIO-FD&C Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩12,600.00 |
52 Week High | ₩19,520.00 |
52 Week Low | ₩11,200.00 |
Beta | 0.62 |
1 Month Change | -1.64% |
3 Month Change | -10.76% |
1 Year Change | -18.92% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -43.24% |
Recent News & Updates
Recent updates
Shareholder Returns
A251120 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -1.8% | 1.4% | 2.4% |
1Y | -18.9% | 21.6% | 12.2% |
Return vs Industry: A251120 underperformed the KR Biotechs industry which returned 21.6% over the past year.
Return vs Market: A251120 underperformed the KR Market which returned 12.2% over the past year.
Price Volatility
A251120 volatility | |
---|---|
A251120 Average Weekly Movement | 3.8% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A251120 has not had significant price volatility in the past 3 months.
Volatility Over Time: A251120's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | n/a | Sang-Hyun Mo | https://www.biofdnc.com |
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, herbal extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, skin moisturizing, anti-inflammation/skin soothing, and anti-oxidation.
BIO-FD&C Co.,Ltd. Fundamentals Summary
A251120 fundamental statistics | |
---|---|
Market cap | ₩109.57b |
Earnings (TTM) | ₩5.59b |
Revenue (TTM) | ₩15.59b |
19.6x
P/E Ratio7.0x
P/S RatioIs A251120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A251120 income statement (TTM) | |
---|---|
Revenue | ₩15.59b |
Cost of Revenue | ₩4.56b |
Gross Profit | ₩11.03b |
Other Expenses | ₩5.44b |
Earnings | ₩5.59b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 642.29 |
Gross Margin | 70.74% |
Net Profit Margin | 35.82% |
Debt/Equity Ratio | 2.0% |
How did A251120 perform over the long term?
See historical performance and comparison